Key result
High adherence to atypical antipsychotics increased CVD/CEV risk by 36% in schizophrenia patients, and typical antipsychotics increased mortality 2- to 3-fold in most cohorts.
Why the study?
This study aimed to investigate the effect of antipsychotic agents on cardiovascular and cerebrovascular diseases and mortality risks in community-dwelling older adults.
Does continued use of antipsychotic agents increase the risk of cardiovascular and cerebrovascular diseases and mortality in older community-dwelling adults compared to ceasing treatment?
Cohort (n=42,650)
Does continued use of antipsychotic agents increase the risk of cardiovascular and cerebrovascular diseases and mortality in older community-dwelling adults compared to ceasing treatment?
Continued use of typical antipsychotics in older adults is associated with a 2- to 3-fold increased risk of mortality, and specific antipsychotic classes increase CVD/CEV risk in patients with schizophrenia or dementia.
No takes yet. Share an insight, caveat, or question.
Supports caution with continued use in older adults; leaves open causality in observational schizophrenia cohorts.
Perreault et al. (2024) conducted a cohort in Older adults using antipsychotic agents (n=42,650). Antipsychotic agents (high adherence ≥ 60%) vs. Ceasing treatment (adherence level < 60%) was evaluated on Cardiovascular and cerebrovascular diseases (CVD/CEV) and mortality. High adherence to atypical antipsychotics increased CVD/CEV risk by 36% in schizophrenia patients, and typical antipsychotics increased mortality 2- to 3-fold in most cohorts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: